secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001193125-23-139409
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viridian Therapeutics Q1 net loss $68.2M; VRDN-001 chronic TED data expected June/July 2023
--------------------------------------------------------------------------------

- Net loss of $68.2M for Q1 2023 vs. $25.7M in Q1 2022; R&D expenses $50.7M including $15M upfront to Enable Injections.
- Cash and short-term investments $373.9M at March 31, 2023, down from $424.6M at Dec 31, 2022; expected to fund into H2 2025.
- Topline data from VRDN-001 proof-of-concept study in chronic TED expected June/July 2023; THRIVE-2 Phase 3 initiation planned mid-2023.
- Lead subcutaneous (SC) program selection expected year-end 2023; IND for VRDN-003 to be filed Q2 2023.
- Appointed Tony Casciano as CCO, Thomas Ciulla as CDO, and other senior executives during Q1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312523139409/0001193125-23-139409-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312523139409/d473560d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-139409

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer